Masako Yamaji
Pfizer R&D Japan
Tokyo, Japan
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
Journal: Vaccine
Published: November 13, 2023
A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: October 26, 2023
Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older.
Journal: Vaccine
Published: August 23, 2023
A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults.
Journal: Vaccine
Published: December 20, 2018
Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.
Journal: The Pediatric infectious disease journal
Published: June 30, 2015
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial.
Journal: Human vaccines & immunotherapeutics
Published: November 27, 2014
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
Journal: The Pediatric infectious disease journal
Published: March 30, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026